NCT06654193View on ClinicalTrials.gov

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2028

Conditions
Acute Kidney Injury
Interventions
DRUG

Allogeneic HB-adMSCs

Allogeneic HB-adMSCs

DRUG

Normal Saline

Sterile Saline Solution

Trial Locations (3)

35294

The University of Alabama at Birmingham, Birmingham

77479

The University of Texas Health Science Center at Houston (UTHealth Houston), Houston

94143

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

The University of Texas Health Science Center, Houston

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

University of Alabama at Birmingham

OTHER

lead

Hope Biosciences LLC

INDUSTRY

NCT06654193 - Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury | Biotech Hunter | Biotech Hunter